168 related articles for article (PubMed ID: 37580710)
21. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
Mala U; Baral TK; Somasundaram K
BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
[TBL] [Abstract][Full Text] [Related]
22. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
23. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
Al-Sammarraie N; Ray SK
Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
[TBL] [Abstract][Full Text] [Related]
24. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
25. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
26. Genome-scale CRISPR-Cas9 screening stratifies pancreatic cancer with distinct outcomes and immunotherapeutic efficacy.
Wang L; Fu D; Weng S; Xu H; Liu L; Guo C; Ren Y; Liu Z; Han X
Cell Signal; 2023 Oct; 110():110811. PubMed ID: 37468054
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
[TBL] [Abstract][Full Text] [Related]
28. A simplified approach for the molecular classification of glioblastomas.
Le Mercier M; Hastir D; Moles Lopez X; De Nève N; Maris C; Trepant AL; Rorive S; Decaestecker C; Salmon I
PLoS One; 2012; 7(9):e45475. PubMed ID: 23029035
[TBL] [Abstract][Full Text] [Related]
29. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel autophagy-related prognostic signature and small molecule drugs for glioblastoma by bioinformatics.
Wang D; Jiang Y; Wang T; Wang Z; Zou F
BMC Med Genomics; 2022 May; 15(1):111. PubMed ID: 35550147
[TBL] [Abstract][Full Text] [Related]
32. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
33. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
35. MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells.
Dong Z; Zou J; Li J; Pang Y; Liu Y; Deng C; Chen F; Cui H
Cancer Med; 2019 Dec; 8(18):7793-7808. PubMed ID: 31691527
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype.
Lv SQ; Fu Z; Yang L; Li QR; Zhu J; Gai QJ; Mao M; He J; Qin Y; Yao XX; Lan X; Wang YX; Lu HM; Xiang Y; Zhang ZX; Huang GH; Yang W; Kang P; Sun Z; Shi Y; Yao XH; Bian XW; Wang Y
Theranostics; 2022; 12(1):459-473. PubMed ID: 34987659
[No Abstract] [Full Text] [Related]
37. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
38. The lncRNA RP3-439F8.1 promotes GBM cell proliferation and progression by sponging miR-139-5p to upregulate NR5A2.
Qi J; Pan L; Yu Z; Ni W
Pathol Res Pract; 2021 Jul; 223():153319. PubMed ID: 33991848
[TBL] [Abstract][Full Text] [Related]
39. A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR.
Al-Mayhani TF; Heywood RM; Vemireddy V; Lathia JD; Piccirillo SGM; Watts C
Neuro Oncol; 2019 Jun; 21(6):719-729. PubMed ID: 30590711
[TBL] [Abstract][Full Text] [Related]
40. A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma.
Zhang C; Wang M; Ji F; Peng Y; Wang B; Zhao J; Wu J; Zhao H
Biomed Res Int; 2021; 2021():8872977. PubMed ID: 33553434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
